Abstract Severe coronavirus (COVID-19) infection has been reportedly associated with a
high risk of thromboembolism. Developing macrovascular thrombotic complications …

Introduction Emerging evidence points to an association between severe clinical
presentation of COVID-19 and increased risk of thromboembolism. One-third of patients …

Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily …

Introduction The first patients with Coronavirus disease 2019 (COVID-19) emerged at the
end of 2019. This novel viral infection demonstrated unique features that include …

COVID-19 is an infectious disease caused by the SARS COV-2 virus. Patients with COVID-
19 are susceptible to thrombosis due to excessive inflammation, platelet activation …

Background: Coronavirus Disease 2019 (COVID-19) is associated with Coagulopathy
(CAC) and Venous Thromboembolism (VTE). These are well-reported complications of …

Emerging evidence shows that the recent pandemic of coronavirus disease 19 (COVID-19)
is characterized by coagulation activation and endothelial dysfunction. This increases the …

Emerging evidences prove that the ongoing pandemic of coronavirus disease 2019 (COVID-
19) is strictly linked to coagulopathy even if pneumonia appears as the major clinical …

The Coronavirus Disease 2019 (COVID-19) pandemic has resulted in significant morbidity
and mortality worldwide. Although initial reports concentrated on severe respiratory illness …

The novel Corona virus infection (Covid-19) first identified in China in December 2019 has
rapidly progressed in pandemic leading to significant mortality and unprecedented …